Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of levamlodipine + bisoprolol tablets for primary hypertension inadequately controlled after monotherapy
ChiCTR2400081022Phase 3Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Levamlodipine and bisoprolol in essential hypertension (5 arms), sponsored by Peking University First Hospital. Primary endpoint: Change from baseline in seated diastolic blood pressure at week 8. Started Jan 2024; status: recruiting.
02
Drugs
Levamlodipinebisoprolol
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2400081022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081022.